Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer

Beets, Geerard L.; Penninckx, Freddy; Schiepers, Christiaan; Filez, Ludo; Mortelmans, Luc; Kerremans, Raymond; Aerts, Raymond; Rao, Maohua

doi:10.1002/bjs.1800811136

Cited by 168 publications

(59 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most patients with NSGCT mature teratoma was found in the residual mass (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). In five of them (16)(17)(18)(19)(20) FDG uptake was found (SUV 1.7-3.7).…”

Section: Resultsmentioning

confidence: 99%

“…In five of them (16)(17)(18)(19)(20) FDG uptake was found (SUV 1.7-3.7). On visual analysis, only patients 16 and 17 had a suspect lesion at PET.…”

Section: Resultsmentioning

confidence: 99%

“…A relatively new method of staging, 18 fluoro-2-deoxyglucose PET (FDG-PET), might be useful to overcome the diagnostic problems in (re)staging GCTs. The glucose analogue FDG is a radiopharmaceutical that allows in vivo evaluation of glucose metabolism with PET.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Spermon¹,

et al. 2002

View full text Add to dashboard Cite

Objective To investigate the role of 18 fluoro-2-deoxyglucose positron emission tomography (FDG-PET) tumorous residual mass the FDG-PET scan was clearly positive; in four of 12 with mature teratoma and inflammation components retroperitoneally, the FDG-PET was also positive. In contrast, eight patients with solitary mature teratoma had a negative PET result. In four of five patients with necrosis after chemotherapy the PET result was correctly negative. All eight patients on surveillance had a negative PET scan and were free of disease at median (range) of 14 (8-18) months. Interestingly, of the 12 patients with a correct negative PET result, 11 had no mature teratoma in their primary tumour. Nine of 10 patients with SGCT were correctly staged. Two FDG-PET studies showed increased uptake; in one, a viable seminomatous mass was found and in the other there was inflammation in the residual mass. In all other patients the FDG-PET scan correctly predicted absence of viability in the residual mass. Conclusions In primary staging, FDG-PET has no benefit over CT. In re-staging, a negative FDG-PET result predicts fibrotic residual mass in seminomatous GCT. Moreover, it could be useful to predict fibrotic residual mass in NSGCT in those patients with no teratoma component in their primary tumour.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In five of them (16)(17)(18)(19)(20) FDG uptake was found (SUV 1.7-3.7). On visual analysis, only patients 16 and 17 had a suspect lesion at PET.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Spermon¹,

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Unexpected extrahepatic metastases were detected in 14 locations in ten patients. In a previous study on 35 patients, Beets et al from the same group, evaluated the clinical impact of PET on management [148]. Sixteen patients presented with "resectable" metastases, eight with resectable pelvic recurrences, eight with a presacral mass of uncertain nature and three with an isolated increase in the carcinoembryonic antigen (CEA) level.…”

Section: Staging Of Patients With Suspected or Demonstrated Recurrencesmentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

“…Whole-body position emission tomography, using fluoro-deoxyglucose (FDG-PET) with 18 F as the position emitting isotope, has a sensitivity as high as 92% to 100%, with a specificity of 85% to 100%. [22][23][24][25][26][27] Schiepers et al 25 reported a 93% sensitivity with FDG-PET compared with 60% with CT. Radioimmunodetection with monoclonal antibodies may also be useful in select cases. In some reports, indium 111 CYT-103 (OncoScint, Cytogen, Princeton, NJ) appeared to be more sensitive than CT in detecting lesions outside the liver.…”

Section: Evaluation Of the Patient With Hepatic Metastasesmentioning

confidence: 99%

Management of hepatic metastases

Choti

Bulkley

1999

Liver Transpl

View full text Add to dashboard Cite

Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms. Copyright 1999 by the American Association for the Study of Liver DiseasesA s many as 50% of the patients with a primary malignancy will eventually develop metastases in the liver, a percentage greater than for any other organ, including the lung. Although primary tumors that drain principally into the portal circulation are more likely than others to develop hepatic metastases, many tumors arising in other sites, such as the breast and lung, also commonly develop hepatic metastases. Although the liver represents a common site of spread from many of these solid tumors, isolated hepatic metastases most commonly occur from colorectal and neuroendocrine tumors. Other less common malignancies also can metastasize predominantly to the liver. For most other solid malignancies, the pattern of metastatic disease is most often that of generalized dissemination. Colorectal MetastasesCancer of the colon and rectum is the third most commonly diagnosed cancer in the United States. An estimated 131,600 new cases will have been discovered in 1998, comprising 11% of new cancer diagnoses. 1 An estimated 56,500 deaths will occur from colorectal cancer that year, comprising 10% of all cancer deaths. 1 Although mortality from largebowel cancer has been improving over the past 30 years, largely because of improvements in early detection, diagnosis, and treatment, approximately 50% of the patients with colorectal cancer eventually die of their neoplastic disease. 1 The liver is the most commonly involved organ in patients with metastatic colorectal cancer. Approximately 20% of these patients have clinically recognizable liver metastases at the time of their primary diagnosis. 1,2 After resection of a primary colorectal cancer in the absence of apparent metastatic disease, approximately 50% of the patients will subsequently manifest metastatic liver disease. Given these figures,...

show abstract

Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer

Cited by 168 publications

References 16 publications

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Management of hepatic metastases

Contact Info

Product

Resources

About

Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer

Cited by 168 publications

References 16 publications

The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Management of hepatic metastases

Contact Info

Product

Resources

About

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours

The role of ¹⁸fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours